Lori Kunkel

Lori Kunkel has over 20 years of experience in the biotechnology industry, specializing in oncology drug development, strategy, and biotech startups. Current roles include serving as a Board Member at Maverick Therapeutics and Nurix Therapeutics, as well as Clinical and Scientific Advisor at multiple firms such as Atreca, Inc., Oryzon, and Rain Therapeutics. Lori Kunkel previously held the position of Acting Chief Medical Officer and Board Member at Loxo Oncology. Educational qualifications include an MD in Internal Medicine from Baylor College of Medicine and further training at prestigious institutions such as the University of Southern California and the David Geffen School of Medicine at UCLA.